文献速递临床试验与 GCP流行病学与生物统计

长期补充维生素D3对抑郁风险与情绪评分的影响:随机临床试验

Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

结论不支持用维生素D3预防抑郁。

要点

  • 50岁以上无临床相关抑郁症状成人补充维生素D3未降低抑郁发生或复发风险。
  • 维生素D3对情绪评分(PHQ-8)变化无显著影响,差异未达最小临床重要差值0.5分。
  • 中位治疗5.3年、90.5%完成试验,结果不支持维生素D3用于抑郁预防。

核心结论

  • 在50岁以上无临床相关抑郁症状的成人中,维生素D3对比安慰剂未显著改变抑郁或临床相关抑郁症状的发生与复发风险,也未显著改变情绪评分。
  • 研究结果不支持在成人中使用维生素D3预防抑郁。

研究设计与样本

  • 采用2×2析因设计随机分配维生素D3(2000 IU/d胆钙化醇)和鱼油或安慰剂;9181名分配至维生素D3,9172名分配至匹配安慰剂。
  • 随机化时间为2011年11月至2014年3月,随机治疗于2017年12月31日结束,该日为最终随访日期。

主要发现

  • 中位治疗持续时间5.3年,90.5%完成试验(试验结束时存活者中93.5%完成)。
  • 抑郁发生率或复发率在两组间无显著差异。
  • 情绪评分随时间变化在两组间无显著差异;PHQ-8评分变化的平均差异为0.01分(95%CI -0.04-0.05分),与零无显著差异。

关键数值与推荐

  • 主要结局为抑郁或临床相关抑郁症状风险(新发与复发病例合计)及情绪评分平均差异。
  • 情绪评分采用8项患者健康问卷抑郁量表(PHQ-8),评分范围0分(症状最少)至24分(症状最多),评分变化的最小临床重要差异为0.5分。
  • 维生素D3剂量为2000 IU/d胆钙化醇。
  • PHQ-8评分变化平均差异:0.01分(95%CI -0.04-0.05分)。

临床怎么用

  • 对于50岁以上无临床相关抑郁症状的成人,不应以预防抑郁为目的常规处方维生素D3。
  • 维生素D3补充决策应基于其他明确适应症,而非抑郁预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Low levels of 25-hydroxyvitamin D have been associated with higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials. OBJECTIVE: To test the effects of vitamin D3 supplementation on late-life depression risk and mood scores. DESIGN, SETTING, AND PARTICIPANTS: There were 18 353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25 871 adults in the US. There were 16 657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017, and this was the final date of follow-up. INTERVENTION: Randomized assignment in a 2 × 2 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 were randomized to vitamin D3 and 9172 were randomized to matching placebo. MAIN OUTCOMES AND MEASURES: The primary outcomes were the risk of depression or clinically relevant depressive symptoms (total of incident and recurrent cases) and the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms] to 24 points [most symptoms]; the minimal clinically important difference for change in scores was 0.5 points). RESULTS: Among the 18 353 randomized participants (mean age, 67.5 [SD, 7.1] years; 49.2% women), the median treatment duration was 5.3 years and 90.5% completed the trial (93.5% among those alive at the end of the trial). Risk of depression or clinically relevant depressive symptoms was not significantly different between the vitamin D3 group (609 depression or clinically relevant depressive symptom events; 12.9/1000 person-years) and the placebo group (625 depression or clinically relevant depressive symptom events; 13.3/1000 person-years) (hazard ratio, 0.97 [95% CI, 0.87 to 1.09]; P = .62); there were no significant differences between groups in depression incidence or recurrence. No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). CONCLUSIONS AND RELEVANCE: Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with vitamin D3 compared with placebo did not result in a statistically significant difference in the incidence and recurrence of depression or clinically relevant depressive symptoms or for change in mood scores over a median follow-up of 5.3 years. These findings do not support the use of vitamin D3 in adults to prevent depression. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01169259 and NCT01696435.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Okereke OI, Reynolds CF, Mischoulon D, et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2020. PMID: 32749491. doi:10.1001/jama.2020.10224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。